Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Cytometry B Clin Cytom. 2020 Oct 5;100(4):497–508. doi: 10.1002/cyto.b.21961

Figure 3. Impact of daratumumab and elotuzumab administration on the expression of different surface antigens.

Figure 3.

A total of 5 bone marrow samples from patients with plasma cell neoplasms were tested. These samples were incubated with 10 μg/mL of daratumumab or 100 μg/ml of elotuzumab prior to surface staining. The resultant staining intensity of each marker was normalized to untreated samples. 95% confidence intervals are plotted.